In a significant boost to biomedical innovation in Andhra Pradesh, Ipseity Diagnostics and Research, a U.S.-based molecular diagnostics company, has entered into a scientific collaboration with Vignan’s Foundation for Science, Technology and Research. Through this partnership, the institutions aim to introduce advanced transcriptomics, low-cost PCR technologies and Next Generation Sequencing (NGS) capabilities in the State, thereby strengthening its molecular research ecosystem.
MoU Formalised at University Campus
The two institutions formally exchanged the Memorandum of Understanding (MoU) at the Vignan’s Foundation campus on Friday, December 12, 2025. The ceremony took place in the presence of Chairman Lavu Rathaiah, Vice-Chancellor P. Nagabhushan and Advisor M. Malakondaiah.
Representing Ipseity Diagnostics, CEO Dr Sandeep Nadendla and Chief Medical Officer Dr Kalyan Chakravarthy K. signed the agreement. From Vignan’s Foundation, Prof. P.M.V. Rao and Prof. Vijaya Ramu Dirisala represented the academic institution.
Advancing Research from Bench to Bedside
According to both institutions, the collaboration will accelerate efforts to translate molecular science from bench to bedside. In particular, the partnership focuses on developing innovative diagnostic solutions for conditions such as sepsis, drug-resistant and uncontrolled infections, and other critical illnesses. As a result, patients could benefit from faster and more precise diagnostic interventions.
Focus on Affordable, Indigenous Technologies
At the same time, the research initiative aims to develop indigenous and affordable diagnostic technologies tailored specifically to the needs of the Indian healthcare system. By prioritising cost-effective innovation, the collaboration seeks to improve access to advanced diagnostics across diverse clinical settings.
Andhra Pradesh Emerges as a Biomedical Research Hub
As reported by The Hindu, commenting on the collaboration, Dr Kalyan Chakravarthy said the partnership positions Andhra Pradesh as an emerging hub for high-end biomedical research. Moreover, he noted that the initiative has the potential to benefit millions of patients by enabling faster, more accurate and cost-effective diagnostic tools.